Biohaven's Opakalim Shows Strong Efficacy in Epilepsy Trials, Shares Gain
BHVN sits 35% above its 52-week low of $7.48.
Summary
Biohaven reported positive new data from Phase 2/3 studies of its epilepsy treatment, Opakalim. A randomized trial showed a longer time before experiencing a second generalized tonic-clonic seizure, and an open-label study demonstrated that 54% of patients achieved over 50% reduction in seizure frequency. This positive development for Opakalim in epilepsy is significant, especially following previous clinical trial failures for the drug in MDD and bipolar disorder. The strong late-stage data de-risks the drug's path to market in a new indication, potentially opening a new revenue stream. Top-line results from the first of two Phase 2/3 studies are expected in the second half of 2026.
At the time of this announcement, BHVN was trading at $10.09 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.